“`html
Karyopharm Therapeutics (KPTI) shares rose by 27.9% to close at $7.48 on the last trading session, fueled by higher-than-average trading volume. This increase comes after a 7.3% decline over the past four weeks, driven by positive investor sentiment regarding its only marketed product, Xpovio (selinexor), which is approved for multiple myeloma and B-cell lymphoma.
The company is set to report a quarterly loss of $3.67 per share, reflecting a year-over-year change of +5.9%. Expected revenues are $40.2 million, up 3.7% year-over-year. The consensus EPS estimate has remained unchanged over the last 30 days, and KPTI currently holds a Zacks Rank of #3 (Hold).
“`
